Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer

NCT05143229 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT05143229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05143229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer
Lead sponsor
University of Kansas Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 28, 2022
Completion date
December 31, 2026
Enrollment
18 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer